Stony Brook Medicine Anti-Inflammatory Trial
ConditionMajor Depressive Disorder
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-65
SponsorStony Brook University
About this trial
This is an experimental study designed to measure the effect of celecoxib or minocycline on depressive symptoms in unipolar and bipolar depression. Participants will be equally randomized to either celecoxib or minocycline. All participants will complete a battery of clinical and psychological assessments prior to treatment assignment, and again after treatment completion, to assess any changes or improvements in depression.
Eligibility criteria
Qualifiers
Current consent form signed
Capacity to give informed consent
Age range 18-65 (inclusive)
Diagnosis of MDD or bipolar depression and currently in a major depressive episode
Disqualifiers
Hypersensitivity to celecoxib, minocycline, tetracyclines, sulfonamides, aspirin, other NSAIDs, or any component of the formulation; previous asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
History of myocardial infarction or current cardiac condition
Heptic impairment, heart failure, severe renal impairment, recent GI bleed, history of peptic ulcer disease, anemia or any other contraindication for celecoxib or minocycline
Poor CYP2C9 metabolizer
Trial design
Treatments tested in this trial
- Celecoxib
- Minocycline
Treatment groups
42 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov